A clinical trial to compare and study the effects of already approved drug teripressin given by continuous infusion vs Intermittent boluses in patients with chronic liver disease induced acute kidney injury.

Open labelled randomized control study on continuous intravenous infusion versus intravenous boluses of terlipressin in the management of HRS - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074406

Enrollment

Registered

2024-09-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: Terlipressin infusion: Terlipressin will be administered initially at a dose of 2mg/day by continuous infusion. Response to treatment will be evaluated every 48 hours. If serum creatini

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed case of cirrhosis of liver. 2. Age more than 18 years. 3. Diagnosis of hepatorenal syndrome as defined by modified criteria of internal club of ascites.

Exclusion criteria

Exclusion criteria: 1. Septic shock. 2. Coronary Artery Disease. 3. Hepatocellular carcinoma BCLCD 4. Post Renal AKI

Design outcomes

Primary

Measure	Time frame
Response to treatment: 1. Complete response. 2. Partial response 3. No responseTimepoint: Treatment will be continued till complete resolution of HRS AKI or Maximum of 14 days of treatment. Treatemnt will be discontinued in patients who develop serious adverse effects or exit from the study.	—

Secondary

Measure	Time frame
Safety of treatment defined as prevalence of adverse events in both the groupsTimepoint: Till end of treatemnt	—

Countries

India

Contacts

Public ContactBeeravelli Rajesh

Aster Medcity

anjalaarth@gmail.com9847034787

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026